These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 23574579)

  • 1. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
    Raskob G; Büller H; Prins M; Segers A; Shi M; Schwocho L; van Kranen R; Mercuri M;
    J Thromb Haemost; 2013 Jul; 11(7):1287-94. PubMed ID: 23574579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
    Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
    J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
    Nakamura M; Wang YQ; Wang C; Oh D; Yin WH; Kimura T; Miyazaki K; Abe K; Mercuri M; Lee LH; Segers A; Büller H
    J Thromb Haemost; 2015 Sep; 13(9):1606-14. PubMed ID: 26179767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
    Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
    Sprynger M
    Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
    van Es N; Di Nisio M; Bleker SM; Segers A; Mercuri MF; Schwocho L; Kakkar A; Weitz JI; Beyer-Westendorf J; Boda Z; Carrier M; Chlumsky J; Décousus H; Garcia D; Gibbs H; Kamphuisen PW; Monreal M; Ockelford P; Pabinger I; Verhamme P; Grosso MA; Büller HR; Raskob GE
    Thromb Haemost; 2015 Nov; 114(6):1268-76. PubMed ID: 26271200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MP; Cohen AT; Meyer G; Grosso MA; Raskob G; Weitz JI; Zhang G; Buller H
    Thromb Haemost; 2016 Sep; 116(4):747-53. PubMed ID: 27440518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
    Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
    Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban: an update on the new oral direct factor Xa inhibitor.
    Bounameaux H; Camm AJ
    Drugs; 2014 Jul; 74(11):1209-31. PubMed ID: 25034361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
    Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
    Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.